EUCTR2012-005513-40-FI进行中（未招募）不适用
Histamine H2 antagonism as adjuvant therapy in treatment resistant schizophrenia
Jesper Ekelund0 个研究点目标入组 140 人开始时间: 2013年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •18-65 year-old men and women with a ICD-10 diagnosis of schizophrenia (F20.00-20.39, F20.5, F20.9) who have had the disorder for at least 5 years and who are on disability pension. (This means that their treatment response is not satisfactory and for the purpose of this study, the subjects are potentially treatment resistant).
- •No changes in schizophrenia treatment within 12 weeks before study inclusion.
- •Written informed consent
- •The subjects must fulfil schizophrenia criteria both according to DSM-IV (295.10, .20, .30, .60, .90) (American Psychiatric association) and the Research Diagnostic Criteria for schizophrenia (RDC) [40]. They must also have at least mild residual symptoms (CGI 3 points). The DSM-IV diagnosis will be verified by use of the SCID-I [41]. The DSM-IV is clearly the most commonly used in psychiatric research, so this is important to be able to generalize the findings. However, several previous studies have used the RDC, so to be able to compare the results, we will diagnose the patients according to both systems.
- •Women of child-bearing age will be included only of they use adequate contraception, or if we can otherwise verify that the subject is not pregnant (s-HCG), the possibility of pregnancy is negligible (e.g. the personnel of the housing facility reports that the person has not had sexual relationships for years) and the subject approves to remain sexually abstinent for the duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 140
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Patients will be excluded if they have any of the following criteria
- •Epilepsy or a history of unclear seizures, stroke, Parkinson’s disease, AIDS
- •History of substance addiction or abuse within 3 months prior to enrolment.
- •Individuals who are deemed at risk for aggressive behaviour or suicide are likewise ex-cluded.
- •If their laboratory tests, EKG or other clinical observation warrants exclusion, they will be excluded
- •Women who are pregnant or breast-feeding subjects will not be included in the study.
- •Patients with any serious unstable physical illness will also be excluded
- •Patients who have been deemed to be legally incapacitated according to Finnish or Swedish law.
- •Use of H2-antagonists
- •Known allergy to famotidine or any other component of Famotidine Hexal will be ex-cluded.
- •Ongoing treatment with clozapine and dixyrazine.
研究者
相似试验
进行中（未招募）
不适用
Histamine H2 antagonism as adjuvant therapy in treatment resistant schizophreniaMedDRA version: 17.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2012-005513-40-SEHYKS Psykiatrikeskus140
已完成
4 期
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant SchizophreniaSchizophreniaNCT00565175Jesper Ekelund30
Unknown
2 期
Famotidine in SchizophreniaSchizophreniaNCT01946295Jesper Ekelund140
已完成
不适用
Therapeutic effect of a histamine H2 receptor antagonist on prokinetic agent-resistant symptomatic chronic gastritischronic gastritisJPRN-UMIN000002248Shimane University20
招募中
不适用
Therapeutic effect of a histamine H2 receptor antagonist on proton pump inhibitor-resistant symptomatic chronic gastritischronica gastritisJPRN-UMIN000002247Shimane University School of Medicine10